Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits

被引:27
作者
Burke, Brian [1 ]
Gomez-Roman, Victor Raul [1 ]
Lian, Ying [1 ]
Sun, Yide [1 ]
Kan, Elaine [1 ]
Ulmer, Jeffrey [1 ]
Srivastava, Indresh K. [1 ]
Barnett, Susan W. [1 ]
机构
[1] Novartis Vaccines & Diagnost, Emeryville, CA 94608 USA
关键词
HIV-1; Neutralization; Adjuvants; MF59; CpG; Multivalent; HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; POLYVALENT DNA PRIME; GM-CSF DNA; IMMUNE-RESPONSES; RHESUS MACAQUES; DENDRITIC CELLS; PARTIAL DELETION; HUMAN VOLUNTEERS; CLADE-A;
D O I
10.1016/j.virol.2009.02.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Improving the potency, breadth, and durability of neutralizing antibody responses to HIV are major challenges for HIV vaccine development. To address these challenges, the studies described evaluate in rabbits the titers, breadth, and epitope specificities of antibody responses elicited by HIV envelope subunit vaccines adjuvanted with MF59 with or without CpG oligodeoxynucleotide (ODN). Animals were immunized with trimeric o-gp140 Delta V2 derived from subtype B HIV-1(SF162) or subtype C HIV-1(TV1), or proteins from both strains. Immunization with SF162 or TV1 with MF59/CpG elicited higher titers of binding and neutralizing antibodies to SF162 than monovalent immunization with MF59 alone (P<0.01). Bivalent immunization increased binding and neutralizing antibody titers over single envelope immunization in MF59 (P<0.01). Bivalent immunization also improved neutralization breadth. Epitope mapping indicated neutralizing activity in rabbits was directed to V3 and V4. Overall, our data Suggests that a multivalent vaccination approach with MF59 and CpG can enhance humoral responses to HIV-1. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:147 / 156
页数:10
相关论文
共 50 条
[1]   Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques [J].
Azizi, Ali ;
Anderson, David E. ;
Torres, Jose V. ;
Ogrel, Andrei ;
Ghorbani, Masoud ;
Soare, Catalina ;
Sandstrom, Paul ;
Fournier, Jocelyne ;
Diaz-Mitoma, Francisco .
JOURNAL OF IMMUNOLOGY, 2008, 180 (04) :2174-2186
[2]   The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region [J].
Barnet, SW ;
Lu, S ;
Srivastava, I ;
Cherpelis, S ;
Gettie, A ;
Blanchard, J ;
Wang, S ;
Mboudjeka, I ;
Leung, L ;
Lian, Y ;
Fong, A ;
Buckner, C ;
Ly, A ;
Hilt, S ;
Ulmer, J ;
Wild, CT ;
Mascola, JR ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (12) :5526-5540
[3]   Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries [J].
Boots, LJ ;
McKenna, PM ;
Arnold, BA ;
Keller, PM ;
Gorny, MK ;
Zolla-Pazner, S ;
Robinson, JE ;
Conley, AJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (18) :1549-1559
[4]   Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody [J].
Brunel, FM ;
Zwick, MB ;
Cardoso, RMF ;
Nelson, JD ;
Wilson, IA ;
Burton, DR ;
Dawson, PE .
JOURNAL OF VIROLOGY, 2006, 80 (04) :1680-1687
[5]   Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate [J].
Chakrabarti, BK ;
Ling, X ;
Yang, ZY ;
Montefiori, DC ;
Panet, A ;
Kong, WP ;
Welcher, B ;
Louder, MK ;
Mascola, JR ;
Nabel, GJ .
VACCINE, 2005, 23 (26) :3434-3445
[6]   DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques [J].
Cherpelis, S ;
Shrivastava, I ;
Gettie, A ;
Jin, X ;
Ho, DD ;
Barnett, SW ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1547-1550
[7]   Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques [J].
Cho, MW ;
Kim, YB ;
Lee, MK ;
Gupta, KC ;
Ross, W ;
Plishka, R ;
Buckler-White, A ;
Igarashi, T ;
Theodore, T ;
Byrum, R ;
Kemp, C ;
Montefiori, DC ;
Martin, MA .
JOURNAL OF VIROLOGY, 2001, 75 (05) :2224-2234
[8]   CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in anti retroviral-treated HIV-infected adults [J].
Cooper, CL ;
Davis, HL ;
Angel, JB ;
Morris, ML ;
Elfer, SM ;
Seguin, I ;
Krieg, AM ;
Cameron, DW .
AIDS, 2005, 19 (14) :1473-1479
[9]   Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine [J].
Cooper, CL ;
Davis, HL ;
Morris, ML ;
Efler, SM ;
Krieg, AM ;
Li, Y ;
Laframboise, C ;
Al Adhami, MJ ;
Khaliq, Y ;
Seguin, I ;
Cameron, DW .
VACCINE, 2004, 22 (23-24) :3136-3143
[10]   Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens:: Comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection [J].
Derby, Nina R. ;
Kraft, Zane ;
Kan, Elaine ;
Crooks, Emma T. ;
Barnett, Susan W. ;
Srivastava, Indresh K. ;
Binley, James M. ;
Stamatatos, Leonidas .
JOURNAL OF VIROLOGY, 2006, 80 (17) :8745-8762